Bolt Biotherapeutics Stock

boltbio.comBioTechFounded: 2015Funding to Date: $64.6MM

Bolt Biotherapeutics is a biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.

Register for Details

For more details on financing and valuation for Bolt Biotherapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Chih-Ping Liu Ph.D
Co-Founder & President
Grant Yonehiro
Chief Business Officer & Chief Operating Officer
Edgar Engleman
Co-Founder & Board Member
Randall Schatzman Ph.D
Chief Executive Officer & Board Member

Board Members

Ashish Khanna Ph.D
NFLS - Pivotal
Edgar Engleman
Ken Harrison
Mahendra Shah
Peter Bisgaard
Peter Moldt
Randall Schatzman Ph.D
Richard Miller MD

Other companies like Bolt Biotherapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

/PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform...
Bolt Biotherapeutics, founded by Stanford immuno-oncology veteran Edgar Engleman, is developing new class of cancer drugs called immune stimulating antibody conjugates. Backed by fresh data from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator, the company is preparing a phase 1 trial.
In cancer lingo, “cold” tumors are cancers that the immune system doesn’t recognize or respond to, even when immune-stimulating drugs are given. Bolt